Publications, Pharmaceutical

Confirming bioequivalence for a generic tiotropium dry powder inhalers

Pharmacokinetic (PK) profiling is a central strategy for the demonstration of bioequivalence in generic dry powder inhaler development.

This paper describes a study in which in vitro testing under clinically relevant conditions, an in silico regional deposition model and a physiologically-based PK simulation model were used together to compare Test and Reference tiotropium products. In vitro testing detected significant batch to batch variability in the Reference product while in silico and PK data, in combination, highlighted the potential for variability in peripheral dose deposition to impact PK profile. The developed in silico model, once validated, has considerable potential to elucidate correlations between in vitro and in vivo data and help generic developers to establish and demonstrate robust bioequivalence.

Download Publication
25 Jun 2020

Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery

Find Out More

This Might Also Be of Interest

14 Dec 2022

Building Digital Solutions To Meet The Unique Therapeutic Needs of Patients

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions

Read More
25 Nov 2022

Analytical Services in the Development of MDIs and DPIs

Brochures, Pharmaceutical, Innovation & Insights, Product Solutions

Read More
16 Nov 2022

From pMDI Device to Therapeutic Effect

Webinars, Pharmaceutical, Sustainability, Device Innovations, Market Insights, Product Solutions

Read More
21 Oct 2022

Physiologically-based Pharmacokinetic Models (PBPK) for OINDPs

Publications, Pharmaceutical, Device Innovations, Market Insights, Product Solutions

Read More
1 2 3 15
Back To Top